We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Sacklers Raise Their Offer to Settle Opioid Lawsuits by More Than $1 Billion
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > Sacklers Raise Their Offer to Settle Opioid Lawsuits by More Than $1 Billion
Sacklers Raise Their Offer to Settle Opioid Lawsuits by More Than  Billion
Health

Sacklers Raise Their Offer to Settle Opioid Lawsuits by More Than $1 Billion

Last updated: February 18, 2022 10:17 pm
Editorial Board Published February 18, 2022
Share
SHARE
07Sacklers facebookJumbo

Members of the billionaire Sackler family have sweetened their cash offer to settle thousands of opioid-related lawsuits against them and their company, Purdue Pharma, offering up to $6 billion, an increase of more than $1 billion from an earlier offer, according to a mediator’s report filed Friday afternoon in bankruptcy court.

But the deal is not done. The Sacklers have not budged from the line they drew in the sand at the outset of the case. In exchange for their billions, they are continuing to demand an end to all civil claims against them related to Purdue and opioids, and that future such claims be prohibited.

Legal experts and the public have criticized efforts by the Sackler family to seek personal protection from liability. It is a shield typically granted to companies seeking bankruptcy restructuring, as Purdue is, but rarely extended to owners who do not file for personal bankruptcy. Eight states and the District of Columbia refused to sign on to an earlier proposal because of the Sackler liability shields.

The mediator, Judge Shelley Chapman, a federal bankruptcy judge, said in her report that a “supermajority” of those states had now agreed to the new offer. But holdouts remain and the deal is not yet done.

The earlier offer included a pledge from the Sacklers of $4.55 billion, including a $225 million federal settlement, to be paid out over roughly nine years. Under the new offer, the Sacklers would pay a total of $5.5 billion, with an additional contribution of up to $500 million, contingent on the sale of their international pharmaceutical companies. The Sacklers would have 18 years to make payments of the additional $1 billion.

The bankruptcy plan requires that the Sackler money, plus billions more from Purdue, be given to funds for states, municipalities and tribes dedicated to the treatment and prevention of opioid addiction, and to compensate victims.

Known as “the Nine,” the holdouts, including Connecticut, Washington, California and Maryland, have been at the mediation table with Purdue and the Sacklers since January.

While negotiations continue, a stay against all litigation against both Purdue and the Sacklers, which has been in place since September 2019, was extended this week and is now set to expire on March 3.

A representative of one branch of the family, descendants of Mortimer Sackler, declined to comment; representatives of another branch, descendants of Raymond Sackler, did not respond to a comment request.

Judge Chapman has requested an extension of the deadline for mediation talks through February 28. Noting that the “unanimous acceptance” that the Sacklers require has not yet been achieved, she suggested that further talks could either reach that end or craft a different set of plans that would not necessitate unanimity.

In the meantime, Purdue, whose plan was rejected by U.S. District Judge Colleen McMahon in December, is pursuing an appeal in the Second Circuit Court of Appeals. Oral arguments are expected in April.

Purdue released a statement saying: “We remain focused on achieving our goal of providing urgently needed funds to the American people for opioid crisis abatement. We believe a global settlement is the swiftest and most cost-effective exit path from Chapter 11 and we will continue working to build consensus as we proceed through the appeal process with the United States Court of Appeals for the Second Circuit.”

You Might Also Like

Measles roars again within the US, topping 1,000 circumstances

Examine finds phthalates might alter genital measurements in 3-year-olds

Needle-free, live-attenuated influenza vaccines with broad safety in opposition to human and avian virus subtypes

Tips up to date for nonoccupational postexposure prophylaxis for HIV

Intraocular irritation extra widespread with aflibercept injections in real-world setting

TAGGED:BankruptciesCompensation for Damages (Law)Opioids and OpiatesPurdue PharmaSackler FamilyStates (US)Suits and Litigation (Civil)The Washington Mail
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Another Far-Right Group Is Scrutinized About Its Efforts to Aid Trump
Politics

Another Far-Right Group Is Scrutinized About Its Efforts to Aid Trump

Editorial Board January 4, 2022
Ukraine Live Updates: U.S. Will Face Higher Gas Prices for ‘as Long as It Takes’ to Defeat Russia, Biden Says
U.S. Fails to Assess Civilian Deaths in Yemen War, Internal Report Says
Human hand present in playground believed to have been dropped by chook
The Sony Honda Mobililty EV “PlayStation” automotive Afeela is prepared for pre-registration

You Might Also Like

Probiotic supplementation might assist cut back chemotherapy uncomfortable side effects in breast most cancers
Health

Probiotic supplementation might assist cut back chemotherapy uncomfortable side effects in breast most cancers

May 10, 2025
Examine exhibits a digital nurse can persuade you to get vaccinated
Health

Examine exhibits a digital nurse can persuade you to get vaccinated

May 10, 2025
Research level to redlining as a ‘excellent storm’ for breast most cancers
Health

Research level to redlining as a ‘excellent storm’ for breast most cancers

May 10, 2025
FDA will enable three new shade components constructed from minerals, algae and flower petals
Health

FDA will enable three new shade components constructed from minerals, algae and flower petals

May 10, 2025

Categories

  • Health
  • Politics
  • Sports
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?